AstraZeneca reports bumper revenue in Q1 2024 on strong drug demand
AstraZeneca continued to see strong earnings boosted primarily by its oncology branch, as well as its respiratory and immunology segment. Pharmaceutical giant AstraZeneca reported its first quarter 2024 earnings on Thursday, seeing extremely robust …